Amgen (NASDAQ: AMGN) director Omar Ishrak granted new stock award

Rhea-AI Filing Summary

ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.

Amgen director Omar Ishrak reported an equity award of 106.1925 shares of Common Stock on a grant/award basis, not an open-market purchase. Following this award, his direct holdings total 6,693.7361 shares of Amgen common stock.

The total includes 418 Dividend Equivalents (DEs) credited under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. These DEs are linked to unvested Restricted Stock Units and will be paid out in shares on a one-to-one basis as those units vest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ISHRAK OMAR

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	106.193	$0.00	--

Holdings After Transaction: Common Stock — 6,693.736 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 106.1925 shares Total holdings after award: 6,693.7361 shares Dividend Equivalents: 418 DEs

3 metrics

Shares granted 106.1925 shares Equity award of Amgen Common Stock reported on Form 4

Total holdings after award 6,693.7361 shares Direct Amgen Common Stock owned following the transaction

Dividend Equivalents 418 DEs DEs under Amgen 2009 Equity Incentive Plan credited to unvested RSUs

Key Terms

Dividend Equivalents (DEs), Restricted Stock Units, Equity Incentive Plan

3 terms

Dividend Equivalents (DEs) financial

"These shares include 418 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

Restricted Stock Units financial

"DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ISHRAK OMAR

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		A		106.1925	A	$0	6,693.7361(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 418 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Andrea A. Robinson, Attorney-In-Fact for Dr. Ishrak	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Omar Ishrak report in his latest Form 4 for Amgen (AMGN)?

Omar Ishrak reported receiving an equity award of 106.1925 shares of Amgen common stock. This was classified as a grant or award acquisition, rather than an open-market trade, and increased his total direct holdings reported in this filing.

How many Amgen (AMGN) shares does Omar Ishrak now hold after this award?

After the reported award, Omar Ishrak directly holds 6,693.7361 shares of Amgen common stock. This figure includes both previously held shares and the newly granted shares disclosed in the Form 4 insider trading report.

What are Dividend Equivalents (DEs) mentioned in Omar Ishrak’s Amgen (AMGN) filing?

The filing notes 418 Dividend Equivalents (DEs) credited under Amgen’s 2009 Equity Incentive Plan. DEs mirror dividends on unvested Restricted Stock Units and are paid out in Amgen common shares on a one-to-one basis as those units vest.

Is Omar Ishrak’s Amgen (AMGN) Form 4 transaction a stock purchase or compensation award?

The Form 4 classifies the transaction as a grant, award, or other acquisition of common stock, coded “A.” This indicates a compensation-related equity award, not an open-market stock purchase, and reflects standard director compensation in shares.

How are fractional Dividend Equivalent shares handled in the Amgen (AMGN) plan?

Under the Amgen equity plan, Dividend Equivalents tied to RSUs are paid in shares on a one-to-one basis, with any remaining fractional share amount settled in cash. This treatment is explicitly described in the Form 4 footnote.